Clinical Trial Update: Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of an oral Cdk inhibitor with an oral BRAF inhibitor in patients with advanced or inoperable BRAF-mutant melanoma has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Oral BRAF inhibitor
• Oral Cdk inhibitor

Snippet

Sponsor: Piramal Enterprises Limited | Conditions: Advanced or Inoperable Malignant Melanoma With BRAF Mutation | Phase 1 | Status: SUSPENDED